

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 212

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣697佰萬元(NTD 697mn)

營業項目Business：

原料藥API (54.59%)

中間體Intermediate (39.62%)

特用化學品 Custom-made chemicals (5.79%)

公司概況 Outline

	Y2013	Y2014
歐洲Europe	36.01%	42.65%
美洲America	22.80%	21.70%
亞洲Asia	24.00%	18.18%
國內Taiwan	17.19%	16.63%
澳洲Australia	0.00%	0.84%
合計Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:
生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:
製劑中之有效成分 Treatable ingredient



下游
Downstream

製劑: 成品藥 Formulation

旭富營業範圍
SCI's businesses

營運概況-IS

Unit: K NTD

	2014	2015 to date
營收Sales	1,491,862	176,262
營業成本COGS	(1,012,509)	(112,193)
毛利Gross Profit	479,353	64,069
毛利率 GP Ratio	32.1%	36.3%
營業費用Operating Expenses	(183,891)	(21,979)
營業利益Operating Income	295,462	42,090
營業外損益Non-Operating In/Ex	39,671	64
稅前淨利 Net Profit before Tax	335,133	42,154
所得稅Income Tax		
本期淨利Net Profit after Tax		

產品組合-Products

Y2012	%		Y2013	%		Y2014	%
V.A.	18.66%		PGA	18.31%		PGA	17.49%
PGA	16.61%		Di-VaNa	16.92%		Di-VANa	10.09%
Di-VaNa	15.97%		S20/38	8.39%		LPF.Na	8.74%
PPON	7.88%		V.A.	8.23%		S20/38	8.25%
Pent-2	4.78%		LPF.Na	6.58%		V.A.	8.15%
5-HMT	4.33%		PPON	6.53%		DBS	4.60%
M85	3.89%		5-HMT	4.51%		5-HMT	4.12%
DBS	2.73%		PEB.Na	3.98%		NaVA	3.65%
M115	2.59%		NaVa	3.34%		Pent-2	3.64%
M74	2.18%		DBS	2.63%		T115	3.33%
Total	79.62%		Total	79.42%		Total	72.06%


No.	Product	%	2015 Sales (NT\$)
1	HOCLQ Sulfate	22.96%	77,267,509
2	PGA	17.57%	59,123,253
3	Di-VANa	9.28%	31,236,894
4	V.A.	8.08%	27,195,862
5	LPF.Na	7.66%	25,765,273
6	DBS	6.16%	20,723,298
7	3-Azetidinol.Hcl	3.83%	12,899,411
8	T115	3.17%	10,682,000
9	Pent-2	3.17%	10,655,189
10	NBE	3.13%	10,548,990

產品介紹Products



產品介紹Product

● Pyrogallolaldehyde (PGA) - Benserazide



✓ 治療帕金森氏症之中間體

Intermediate for Parkinson's Disease


✓ 2個客戶

2 customers

✓ 2015 sales: 59M

產品介紹Product

- Divalproex Sodium (Di-Va)




- ✓ 學名藥於2009推出
- ✓ 10個客戶
- ✓ 2015 sales: 31M

Generic came out in 2009
10 customers


產品介紹Product

Anti-inflammatory (Loxoprofen sodium)



日本市場200-300公噸
Japan market: 200-300MT
2015 sales: 26M

S20/38



臨床藥物
Medication in clinical trial

產品介紹Product

Valproic Acid (VA)




✓ 20個客戶

20 customers

✓ 2015 sales: 27M


產品介紹Product

Sodium Valproate (NaVA)



- ✓ 24 客戶 24 customers
- ✓ 2015 sales: 9M


5-HMT – Ritonavir, Lopinavir




- ✓ 愛滋病藥物中間體
For AIDS treatment
- ✓ 2015 sales: 8M

產品介紹Product

Pentobarbital Sodium (鎮定安眠用, calmative)



Pent-2



產品介紹Product

Antidepressant (Duloxetine)

- ✓ 2013年底專利到期 Patent expired in the end of 2013
- ✓ 2014 sales: 12 M

Antidepressant (S-MMAA)

- ✓ Duloxetine之中間體 intermediate of Duloxetine
- ✓ 2014 sales: 27 M

產品介紹Product

- ✓ 5t: 15.3m sales
- ✓ Hydroxychloroquine sulfate: 18.6 m sales
- ✓ Propafenone: 16 m sales
- ✓ HDFN: 19 m sales

GMP Status(GMP現況)

<i>API</i>	<i>CGMP certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Probucol	2004		2004		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011	2014			
Duloxetine Hydrochloride	2012	2014	2010/2011		
Thiopental acid	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013	2014			
Hydroxychloroquine Sulfate	2014		2014		
Clindamycin Palmitate HCl			2011		
Cyclophosphamide			2012		

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010

簡報完畢



敬請指教